🇺🇸 Fluticasone furoate/umeclidinium/vilanterol in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Angioedema — 1 report (10%)
2. Chest Pain — 1 report (10%)
3. Disseminated Strongyloidiasis — 1 report (10%)
4. Drug Ineffective — 1 report (10%)
5. Drug Ineffective For Unapproved Indication — 1 report (10%)
6. Drug Intolerance — 1 report (10%)
7. Dysphonia — 1 report (10%)
8. Enterococcal Infection — 1 report (10%)
9. Headache — 1 report (10%)
10. Hypersensitivity — 1 report (10%)

Source database →

Frequently asked questions

Is Fluticasone furoate/umeclidinium/vilanterol approved in United States?

Fluticasone furoate/umeclidinium/vilanterol does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Fluticasone furoate/umeclidinium/vilanterol in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.